Genentech reported that the company’s rheumatoid arthritis drug Actemra failed to hit the primary endpoint in a Covid-19 trial, while Vir and GlaxoSmithKline’s antibody against Covid-19 demonstrated 85 percent efficacy.

Gilead Sciences Inc. decided not to pursue the U.S. Food and Drug Administration’s approval of the company’s experimental rheumatoid arthritis treatment, filgotinib, following a meeting with the health regulator.

Kymera Therapeutics entered a strategic collaboration deal with Sanofi focused on developing and commercializing protein degrader therapies that target IRAK4 in immune-inflammatory diseases, such as rheumatoid arthritis.